Innovative Cancer Test Predicts Treatment Needs a Decade in Advance
The study introduces EVOFLUx, a cost-effective computational framework that uses DNA methylation patterns, specifically fluctuating CpGs, to infer the evolutionary history of cancers at clinical scale, revealing insights into tumor growth, subclonal architecture, and prognostic implications across lymphoid malignancies.